0001193125-26-059853
SEC filingZimmer Biomet Holdings, Inc. reported net sales of $8.23 billion for fiscal year 2025, generating operating profit of $1.10 billion and net earnings of $705.1 million. The company's operating cash flow was strong at $1.70 billion, though significant investing activities of $1.98 billion, primarily for business combinations, resulted in a net cash outflow from investing. The balance sheet shows total assets of $23.09 billion with substantial goodwill ($9.95 billion) and intangible assets ($4.72 billion), while long-term debt stands at $6.93 billion. Earnings per share were $4.00 (basic and diluted). The company returned capital to shareholders through $190.3 million in dividends and $487.0 million in share repurchases. No prior year comparative figures are provided in the source data, limiting year-over-year analysis.
Zimmer Biomet Holdings, Inc. reported total net sales of $8.23 billion for the fiscal year ending December 31, 2025. The company achieved operating profit of $1.10 billion and net earnings attributable to Zimmer Biomet Holdings, Inc. of $705.1 million. Basic and diluted earnings per common share were both $4.00. Operating expenses totaled $7.13 billion, consisting of cost of products sold ($2.49B), intangible asset amortization ($665.9M), research and development ($458.5M), selling, general and administrative ($3.26B), restructuring costs ($181.2M), and acquisition-related expenses ($76.9M). The company's operating margin was 13.4%. No prior year comparative figures are provided in the source data, preventing year-over-year performance analysis.
The source data provides only consolidated revenue figures without segment or geographic breakdown. Net sales of $8.23 billion represent the company's total revenue from all operations. No information is provided about revenue by product category, geographic region, or business segment. The document does not disclose specific growth drivers, market share changes, or customer concentration data. Revenue recognition policies and significant customer relationships are not detailed in the provided financial data sections.
The company's gross profit can be calculated as $5.74 billion (net sales of $8.23B minus cost of products sold of $2.49B), resulting in a gross margin of 69.7%. Operating margin was 13.4% ($1.10B operating profit divided by $8.23B net sales). The cost structure shows significant intangible asset amortization ($665.9M) and substantial selling, general and administrative expenses ($3.26B), which together represent 47.7% of net sales. Research and development expenses were $458.5M (5.6% of revenue). The provision for income taxes was $125.7M, representing an effective tax rate of 15.1% on earnings before income taxes of $830.8M.
Operating activities generated $1.70 billion in cash, primarily from net earnings of $705.1M adjusted for $1.09B in depreciation and amortization. Investing activities used $1.98 billion, with $1.39B for business combination investments and $525.0M for capital expenditures ($300.5M for instruments plus $224.5M for other property, plant and equipment). Financing activities provided $326.0M, including $2.49B from senior note proceeds offset by $1.46B in redemptions, $487.0M in share repurchases, and $190.3M in dividends paid. The balance sheet shows total assets of $23.09B, including $9.95B in goodwill and $4.72B in intangible assets. Total liabilities were $10.39B, with $6.93B in long-term debt and $587.1M in current debt portion. Stockholders' equity was $12.71B.
The provided financial data sections do not include management discussion and analysis, forward-looking statements, strategic priorities, or risk factor disclosures. No information is available about guidance for future periods, market trends, competitive positioning, regulatory developments, or operational initiatives. The source material consists exclusively of financial statement data without narrative sections that would provide context about the company's outlook, strategic direction, or management expectations for future performance.